-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Edited by WuXi AppTec Content Team
Gilead Sciences today announced that its antibody-drug conjugate Trodelvy (sacituzumab govitecan) significantly improved overall overall outcomes in a Phase 3 trial of TROPiCS-02 in patients with HR-positive/HER2-negative metastatic breast cancer who had received multiple prior therapie.HR-positive/HER2-negative breast cancer is the most common type of breast cancer, accounting for approximately 70% of all new case.
[1] Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Stud.
Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progres.